{"id":3098,"date":"2019-12-17T16:50:00","date_gmt":"2019-12-17T16:50:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=3098"},"modified":"2025-01-14T22:16:59","modified_gmt":"2025-01-14T22:16:59","slug":"nonalcoholic-fatty-liver-disease-burden-switzerland-2018-2030","status":"publish","type":"post","link":"https:\/\/cdafound.org\/es\/nonalcoholic-fatty-liver-disease-burden-switzerland-2018-2030\/","title":{"rendered":"Carga de enfermedad del h\u00edgado graso no alcoh\u00f3lico - Suiza 2018-2030"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Resumen<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Como resultado de los niveles epid\u00e9micos de obesidad y diabetes mellitus, la enfermedad del h\u00edgado graso no alcoh\u00f3lico (NAFLD) y la esteatohepatitis no alcoh\u00f3lica (NASH) contribuir\u00e1n a aumentar la carga de enfermedades relacionadas con el h\u00edgado en Suiza. Se construy\u00f3 un modelo de Markov para cuantificar la progresi\u00f3n de la fibrosis entre las poblaciones de NAFLD y NASH, y predecir la carga de la enfermedad hasta 2030. La tendencia a largo plazo de la prevalencia de NAFLD se bas\u00f3 en cambios en la prevalencia de la obesidad en adultos. Se aplicaron estimaciones publicadas y datos de vigilancia para construir y validar las proyecciones del modelo. La prevalencia de NAFLD aument\u00f3 hasta 2030 junto con los aumentos previstos en la obesidad en adultos. Para 2030, se estimaba que hab\u00eda 2.234.000 (1.918.000\u20132.553.000) casos de EHGNA, o 24,3% (20,9\u201327,8%) de la poblaci\u00f3n suiza total (todas las edades). Los aumentos en los casos de NASH fueron relativamente mayores que los casos de NAFLD. Se prev\u00e9 que los casos incidentes de enfermedad hep\u00e1tica avanzada aumenten en aproximadamente 40% para 2030, y las muertes hep\u00e1ticas incidentes por NAFLD aumentar\u00e1n de 580 muertes en 2018 a 820 muertes en 2030. El crecimiento continuo de la obesidad, en combinaci\u00f3n con el envejecimiento de la poblaci\u00f3n, resultar\u00e1 en un aumento n\u00famero de casos de enfermedad hep\u00e1tica avanzada y mortalidad relacionada con NAFLD y NASH. Se requiere ralentizar el crecimiento de la obesidad y el s\u00edndrome metab\u00f3lico, junto con futuras terapias potenciales, para reducir la carga de enfermedad hep\u00e1tica.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pa\u00edses:<\/strong> Suiza<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31846507\/\" style=\"border-radius:6px;color:#951b23\" target=\"_blank\" rel=\"noreferrer noopener\">Lea el informe completo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland. A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long-term [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3113,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[24],"publication-author":[747,750,528,535,748,746,749,745,751,522,494,530],"class_list":["post-3098","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-nafld","publication-author-bellentani-s","publication-author-cerny-a","publication-author-dufour-jf","publication-author-estes-c","publication-author-goossens-n","publication-author-jornayvaz-fr","publication-author-mertens-j","publication-author-moriggia-a","publication-author-muellhaupt-b","publication-author-negro-f","publication-author-razavi-h","publication-author-semela-d"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/3098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/comments?post=3098"}],"version-history":[{"count":5,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/3098\/revisions"}],"predecessor-version":[{"id":7487,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/3098\/revisions\/7487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media\/3113"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media?parent=3098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/categories?post=3098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/tags?post=3098"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/publication-author?post=3098"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}